Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,789 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: Ankle Sprain
Interventions: High velocity, low amplitude stretch, Slow, mobilization stretch, Passive Positioning; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Intermittent Theta Burst Stimulation (iTBS), Transcranial Alternating Current Stimulation (tACS), Psychotherapy, Sham (Placebo) Transcranial Alternating Current Stimulation (tACS); Device · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone bromide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Dravet Syndrome
Interventions: Clobazam, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 1 Year to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more

Conditions: Emphysema, COPD
Interventions: IBV® Valve System; Device
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 40 Years to 74 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Mission Viejo, California + 29 more

Conditions: Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions: Sildenafil citrate (open label), Testosterone gel, Placebo gel; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Skin Aging, Skin Wrinkling
Interventions: PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo); Drug
Lead sponsor: Kalpna Kay Durairaj, MD, FACS; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Allergic Conjunctivitis (AC)
Interventions: EBI-005, Placebo Comparator; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 11
States / cities: Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more

Conditions: Binge-Eating Disorder, Obesity
Interventions: Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment); Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes
Interventions: Resveratrol, Placebo; Drug · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Constipation
Interventions: Lubiprostone, Senna; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myocardial Infarction
Interventions: Percutaneous Coronary Intervention (PCI), RO4905417, placebo; Procedure · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 19 Years to 74 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 35
States / cities: Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 31 more

Conditions: Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Interventions: LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2), Bilateral sham procedure control (Part 2); Drug
Lead sponsor: Lyra Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 22
States / cities: Carlsbad, California • La Mesa, California • Roseville, California + 18 more

Conditions: Caregiver
Interventions: Psychosocial Support for Caregiver, Questionnaire Administration, Sham Intervention; Other
Lead sponsor: University of Washington; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Whole grain oats and barley; Other
Lead sponsor: Tufts University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Melanoma
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more

Conditions: Rib Fracture, Rib Fracture Multiple
Interventions: Cryoneurolysis, Local anesthetic peripheral nerve block, Sham Cryoneurolysis, Sham peripheral nerve block; Device · Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: La Jolla, California • Bethesda, Maryland • Boston, Massachusetts + 1 more

Conditions: Critical Illness, Delirium, Cognitive Impairment
Interventions: Guanfacine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atrial Fibrillation
Interventions: Solumedrol, Placebo; Drug
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: D-serine, placebo, Sensory Based remediation paradigm; Drug · Behavioral
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Tibial Fractures
Interventions: CP-533,536, Placebo, Standard of Care; Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 17 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 11
States / cities: Wichita, Kansas • Worcester, Massachusetts • Minneapolis, Minnesota + 7 more

Conditions: Blood Loss, Surgical, Second Trimester Abortion
Interventions: Misoprostol 400mcg buccal, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Post Operative Pain, Nausea
Interventions: Dexamethasone 8mg iv x1, placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prematurity, Development Delay, Premature Birth
Interventions: Recorded Maternal Voice, Placebo Recording; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 28 Weeks to 33 Weeks
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Ankle Sprains and Corticospinal Excitability

CARED : A Novel Rapid Treatment Paradigm for Depression

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

Effect of Testosterone in Men With Erectile Dysfunction

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)

Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

Clinical Assessment of Barley and Oat Phytochemicals

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Pain Following Thoracic Trauma

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

Corticosteroid Pulse After Ablation

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

ACTiF- Assessment of Closed Tibial Fractures

MisOpRostol Effect on Second Trimester Abortion Blood Loss

Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery

Maternal Voice and Quantitative EEG (qEEG)